Drug-drug interaction prediction with learnable size-adaptive molecular substructures

Knowledge-aware contrastive heterogeneous molecular graph learning

Molecular representation learning is pivotal in predicting molecular properties and advancing drug design. Traditional methodologies, which predominantly rely on homogeneous graph encoding, are limited by their inability to integrate external knowledge and represent molecular structures across different levels of granularity. To address these limitations, we propose a paradigm shift by encoding molecular graphs into heterogeneous structures, introducing a novel framework: Knowledge-aware Contrastive Heterogeneous Molecular Graph Learning. This approach leverages contrastive learning to enrich molecular representations with embedded external knowledge. KCHML conceptualizes molecules through three distinct graph views-molecular, elemental, and pharmacological-enhanced by heterogeneous molecular graphs and a dual message-passing mechanism. This design offers a comprehensive representation for property prediction, as well as for downstream tasks such as drug-drug interaction prediction. Extensive benchmarking demonstrates KCHML's superiority over state-of-the-art molecular property prediction models, underscoring its ability to capture intricate molecular features.

Predicting rare drug-drug interaction events with dual-granular structure-adaptive and pair variational representation

Adverse drug-drug interaction events (DDIEs) pose serious risks to patient safety, yet rare but severe interactions remain challenging to identify due to limited clinical data. Existing computational methods rely heavily on abundant samples, failing to identify rare DDIEs. Here we introduce RareDDIE, a metric-based meta-learning model that employs a dual-granular structure-driven pair variational representation to enhance rare DDIE prediction. To further address the challenge of zero-shot DDIE identification, we develop the Biological Semantic Transferring (BST) module, integrating large-scale sentence embeddings to form the ZetaDDIE variant. Our model outperforms existing methods in few-sample and zero-sample settings. Furthermore, we verify that knowledge transfer from DDIE can improve drug synergy predictions, surpassing existing models. Case studies on antiplatelet activity reduction and non-small cell lung cancer drug synergy further illustrate the practical value of RareDDIE. By analyzing the meta-knowledge construction process, we provide interpretability into the model's decision-making. This work establishes an effective computational framework for rare DDIE prediction, leveraging meta-learning and knowledge transfer to overcome key challenges in data-limited scenarios.

Unified Knowledge-Guided Molecular Graph Encoder with multimodal fusion and multi-task learning

The remarkable success of Graph Neural Networks underscores their formidable capacity to assimilate multimodal inputs, markedly enhancing performance across a broad spectrum of domains. In the context of molecular modeling, considerable efforts have been made to enrich molecular representations by integrating data from diverse aspects. Nevertheless, current methodologies frequently compartmentalize geometric and semantic components, resulting in a fragmented approach that impairs the holistic integration of molecular attributes. This constrained scope limits the generalizability and efficacy of such models in downstream applications. A pivotal challenge lies in harmonizing heterogeneous data sources, particularly in addressing the inherent inconsistencies and sparsity within multimodal molecular datasets. To overcome these limitations, we present the Unified Knowledge-Guided Molecular Graph Encoder (UKGE), a groundbreaking framework that leverages heterogeneous graphs to unify the representation of diverse molecular modalities. Unlike prior methods, UKGE reconciles geometric and semantic features through the use of elemental knowledge graphs (KGs) and meta-path definitions by constructing Unified Molecular Graphs, enabling comprehensive and unified molecular representations. It employs an innovative Meta-Path Aware Message Passing mechanism within its molecular encoder, enhancing the integration of multimodal data. Additionally, a multi-task learning strategy balances data from different modalities, further enriching UKGE's capability to embed complex biological insights.Empirical evaluations highlight UKGE's excellence across tasks: DDI prediction achieves 96.91% ACC and 99.14% AUC in warm-start settings, with 83.15% ACC in cold-start scenarios. For CPI prediction, it reaches 0.644 CI on Davis and 0.659 on KIBA. In LBDD, it achieves 99.3% validity, 98.4% uniqueness, and 98.9% novelty, establishing UKGE as a state-of-the-art molecular modeling framework.

MSMDL-DDI: Multi-Layer Soft Mask Dual-View Learning for Drug-Drug Interactions

Drug-drug interactions (DDIs) occur when multiple medications are co-administered, potentially leading to adverse effects and compromising patient safety. However, existing DDI prediction methods often overlook the intricate interactions among chemical substructures within drugs, resulting in incomplete characterization of molecular properties. To address this limitation, we propose a novel model named Multi-Layer Soft Mask Dual-View Learning for Drug-Drug Interactions (MSMDL-DDI), which integrates dual-view learning with multi-layer soft mask graph neural networks to comprehensively capture intra- and inter-molecular interactions. Specifically, our model first employs a multi-layer soft-masked graph neural network to extract key substructures from drug molecule graphs. Subsequently, our model implements a novel dual-view learning strategy to capture intra- and inter-molecular interactions resulting in enriched drug pair representations. Finally, the model predicts the likelihood of DDIs by utilizing a decoder to compute the shared attention scores of these enhanced representations. In addition, experimental results on three real-world datasets show that MSMDL-DDI outperforms nine state-of-the-art methods in both transductive and inductive DDI prediction tasks. Notably, the model achieves an accuracy of 0.9647 on the Twosides dataset for the transductive task, marking a 10.2% improvement over the second-best-performing method.

MOLGAECL: Molecular Graph Contrastive Learning via Graph Auto-Encoder Pretraining and Fine-Tuning Based on Drug-Drug Interaction Prediction

Drug-drug interactions influence drug efficacy and patient prognosis, providing substantial research value. Some existing methods struggle with the challenges posed by sparse networks or lack the capability to integrate data from multiple sources. In this study, we propose MOLGAECL, a novel approach based on graph autoencoder pretraining and molecular graph contrastive learning. Initially, a large number of unlabeled molecular graphs are pretrained using a graph autoencoder, where graph contrastive learning is applied for more accurate representation of the drugs. Subsequently, a full-parameter fine-tuning is performed on different data sets to adapt the model for drug interaction-related prediction tasks. To assess the effectiveness of MOLGAECL, comparison experiments with state-of-the-art methods, fine-tuning comparison experiments, and parameter sensitivity analysis are conducted. Extensive experimental results demonstrate the superior performance of MOLGAECL. Specifically, MOLGAECL achieves an average increase of 6.13% in accuracy, 6.14% in AUROC, and 8.16% in AUPRC across all data sets.

A novel deep sequential learning architecture for drug drug interaction prediction using DDINet

Drug drug Interactions (DDI) present considerable challenges in healthcare, often resulting in adverse effects or decreased therapeutic efficacy. This article proposes a novel deep sequential learning architecture called DDINet to predict and classify DDIs between pairs of drugs based on different mechanisms viz., Excretion, Absorption, Metabolism, and Excretion rate (higher serum level) etc. Chemical features such as Hall Smart, Amino Acid count and Carbon types are extracted from each drug (pairs) to apply as an input to the proposed model. Proposed DDINet incorporates attention mechanism and deep sequential learning architectures, such as Long Short-Term Memory and gated recurrent unit. It utilizes the Rcpi toolkit to extract biochemical features of drugs from their chemical composition in Simplified Molecular-Input Line-Entry System format. Experiments are conducted on publicly available DDI datasets from DrugBank and Kaggle. The model's efficacy in predicting and classifying DDIs is evaluated using various performance measures. The experimental results show that DDINet outperformed eight counterpart techniques achieving [Formula: see text] overall accuracy which is also statistically confirmed by Confidence Interval tests and paired t-tests. This architecture may act as an effective computational technique for drug drug interaction with respect to mechanism which may act as a complementary tool to reduce costly wet lab experiments for DDI prediction and classification.

A Molecular Fragment Representation Learning Framework for Drug-Drug Interaction Prediction

The concurrent use of multiple drugs may result in drug-drug interactions, increasing the risk of adverse reactions. Hence, it is particularly crucial to propose computational methods for precisely identifying unknown drug-drug interactions, which is of great significance for drug development and health. However, most recent studies have limited the drug-drug interaction prediction task to identifying interactions between substructures, overlooking molecular hierarchical information. Moreover, the extracted substructures in these methods are always restricted to have the same number of atoms as contained in the molecular graph, which does not align with real-world facts. In this study, a molecular fragment representation learning framework for drug-drug interaction prediction is introduced. Initially, a fragment extraction module is designed to acquire a series of molecular fragments. Subsequently, to capture more comprehensive features, molecular hierarchical information is effectively integrated, enabling drug-drug interaction prediction by identifying pairwise interactions between molecular fragments of each drug. Comprehensive evaluations demonstrate that the proposed method achieved state-of-the-art performance in both DrugBank and Twosides datasets, particularly achieving an improved accuracy of over 20% for unseen drugs in both two datasets. Furthermore, case studies and visual analysis confirm that the proposed method can accurately identify crucial substructures influencing the interactions, which are basically consistent with functional group structures in reality. In conclusion, this method not only enhances the performance of drug-drug interaction prediction but also offers high interpretability. Source code is freely available at https://github.com/kennysyp/MFR-DDI .

ComNet: A Multiview Deep Learning Model for Predicting Drug Combination Side Effects

As combination therapy becomes more common in clinical applications, predicting adverse effects of combination medications is a challenging task. However, there are three limitations of the existing prediction models. First, they rely on a single view of the drug and cannot fully utilize multiview information, resulting in limited performance when capturing complex structures. Second, they ignore subgraph information at different scales, which limits the ability to model interactions between subgraphs. Third, there has been limited research on effectively integrating multiview features of molecules. Therefore, we propose ComNet, a deep learning model that improves the accuracy of side effect prediction by integrating multiview features of drugs. First, to capture diverse features of drugs, a multiview feature extraction module is proposed, which not only uses molecular fingerprints but also extracts semantic information on SMILES and spatial information on 3D conformations. Second, to enhance the modeling ability of complex structures, a multiscale subgraph fusion mechanism is proposed, which can fuse local and global graph structures of drugs. Finally, a multiview feature fusion mechanism is proposed, which uses an attention mechanism to adaptively adjust the weights of different views to achieve multiview data fusion. Experiments on several publicly available data sets show that ComNet performs better than existing methods in various complex scenarios, especially in cold-start scenarios. Ablation experiments show that each core structure in ComNet contributes to the overall performance. Further analysis shows that ComNet not only converges rapidly and has good generalization ability but also identifies different substructures in the molecule. Finally, a case study on a self-collected data set validates the superior performance of ComNet in practical applications.

HDN-DDI: a novel framework for predicting drug-drug interactions using hierarchical molecular graphs and enhanced dual-view representation learning

BACKGROUND

Drug-drug interactions (DDIs) especially antagonistic ones present significant risks to patient safety, underscoring the urgent need for reliable prediction methods. Recently, substructure-based DDI prediction has garnered much attention due to the dominant influence of functional groups and substructures on drug properties. However, existing approaches face challenges regarding the insufficient interpretability of identified substructures and the isolation of chemical substructures.

RESULTS

This study introduces a novel framework for DDI prediction termed HDN-DDI. HDN-DDI integrates an explainable substructure extraction module to decompose drug molecules and represents them using innovative hierarchical molecular graphs, which effectively incorporates information from real chemical substructures and improves molecules encoding efficiency. Furthermore, the enhanced dual-view learning method inspired by the underlying mechanisms of DDIs enables HDN-DDI to comprehensively capture both hierarchical structure and interaction information. Experimental results demonstrate that HDN-DDI has achieved state-of-the-art performance with accuracies of 97.90% and 99.38% on the two widely-used datasets in the warm-start setting. Moreover, HDN-DDI exhibits substantial improvements in the cold-start setting with boosts of 4.96% in accuracy and 7.08% in F1 score on previously unseen drugs. Real-world applications further highlight HDN-DDI's robust generalization capabilities towards newly approved drugs.

CONCLUSION

With its accurate predictions and robust generalization across different settings, HDN-DDI shows promise for enhancing drug safety and efficacy. Future research will focus on refining decomposition rules as well as integrating external knowledge while preserving the model's generalization capabilities.

A comprehensive review of deep learning-based approaches for drug-drug interaction prediction

Deep learning models have made significant progress in the biomedical field, particularly in the prediction of drug-drug interactions (DDIs). DDIs are pharmacodynamic reactions between two or more drugs in the body, which may lead to adverse effects and are of great significance for drug development and clinical research. However, predicting DDI through traditional clinical trials and experiments is not only costly but also time-consuming. When utilizing advanced Artificial Intelligence (AI) and deep learning techniques, both developers and users face multiple challenges, including the problem of acquiring and encoding data, as well as the difficulty of designing computational methods. In this paper, we review a variety of DDI prediction methods, including similarity-based, network-based, and integration-based approaches, to provide an up-to-date and easy-to-understand guide for researchers in different fields. Additionally, we provide an in-depth analysis of widely used molecular representations and a systematic exposition of the theoretical framework of models used to extract features from graph data.

A Domain Adaptive Interpretable Substructure-Aware Graph Attention Network for Drug-Drug Interaction Prediction

Accurate prediction of drug-drug interaction (DDI) is essential to improve clinical efficacy, avoid adverse effects of drug combination therapy, and enhance drug safety. Recently researchers have developed several computer-aided methods for DDI prediction. However, these methods lack the substructural features that are critical to drug interactions and are not effective in generalizing across domains and different distribution data. In this work, we present SAGAN, a domain adaptive interpretable substructure-aware graph attention network for DDI prediction. Based on attention mechanism and unsupervised clustering algorithm, we propose a new substructure segmentation method, which segments the drug molecule into multiple substructures, learns the mechanism of drug interaction from the perspective of interaction, and identifies important interaction regions between drugs. To enhance the generalization ability of the model, we improve and apply a conditional domain adversarial network to achieve cross-domain generalization by alternately optimizing the cross-entropy loss on the source domain and the adversarial loss of the domain discriminator. We evaluate and compare SAGAN with the state-of-the-art DDI prediction model on four real-world datasets for both in-domain and cross-domain scenarios, and show that SAGAN achieves the best overall performance. Moreover, the visualization results of the model show that SAGAN has achieved pharmacologically significant substructure extraction, which can help drug developers screen for some undiscovered local interaction sites, and provide important information for further drug structure optimization. The codes and datasets are available online at https://github.com/wyx2012/SAGAN .

Multi-relational graph contrastive learning with learnable graph augmentation

Multi-relational graph learning aims to embed entities and relations in knowledge graphs into low-dimensional representations, which has been successfully applied to various multi-relationship prediction tasks, such as information retrieval, question answering, and etc. Recently, contrastive learning has shown remarkable performance in multi-relational graph learning by data augmentation mechanisms to deal with highly sparse data. In this paper, we present a Multi-Relational Graph Contrastive Learning architecture (MRGCL) for multi-relational graph learning. More specifically, our MRGCL first proposes a Multi-relational Graph Hierarchical Attention Networks (MGHAN) to identify the importance between entities, which can learn the importance at different levels between entities for extracting the local graph dependency. Then, two graph augmented views with adaptive topology are automatically learned by the variant MGHAN, which can automatically adapt for different multi-relational graph datasets from diverse domains. Moreover, a subgraph contrastive loss is designed, which generates positives per anchor by calculating strongly connected subgraph embeddings of the anchor as the supervised signals. Comprehensive experiments on multi-relational datasets from three application domains indicate the superiority of our MRGCL over various state-of-the-art methods. Our datasets and source code are published at https://github.com/Legendary-L/MRGCL.

EDDINet: Enhancing drug-drug interaction prediction via information flow and consensus constrained multi-graph contrastive learning

Predicting drug-drug interactions (DDIs) is crucial for understanding and preventing adverse drug reactions (ADRs). However, most existing methods inadequately explore the interactive information between drugs in a self-supervised manner, limiting our comprehension of drug-drug associations. This paper introduces EDDINet: Enhancing Drug-Drug Interaction Prediction via Information Flow and Consensus-Constrained Multi-Graph Contrastive Learning for precise DDI prediction. We first present a cross-modal information-flow mechanism to integrate diverse drug features, enriching the structural insights conveyed by the drug feature vector. Next, we employ contrastive learning to filter various biological networks, enhancing the model's robustness. Additionally, we propose a consensus regularization framework that collaboratively trains multi-view models, producing high-quality drug representations. To unify drug representations derived from different biological information, we utilize an attention mechanism for DDI prediction. Extensive experiments demonstrate that EDDINet surpasses state-of-the-art unsupervised models and outperforms some supervised baseline models in DDI prediction tasks. Our approach shows significant advantages and holds promising potential for advancing DDI research and improving drug safety assessments. Our codes are available at: https://github.com/95LY/EDDINet_code.

ChemNTP: Advanced Prediction of Neurotoxicity Targets for Environmental Chemicals Using a Siamese Neural Network

Environmental chemicals can enter the human body through various exposure pathways, potentially leading to neurotoxic effects that pose significant health risks. Many such chemicals have been identified as neurotoxic, but the molecular mechanisms underlying their toxicity, including specific binding targets, remain unclear. To address this, we developed ChemNTP, a predictive model for identifying neurotoxicity targets of environmental chemicals. ChemNTP integrates a comprehensive representation of chemical structures and biological targets, improving upon traditional methods that are limited to single targets and mechanisms. By leveraging these structural representations, ChemNTP enables rapid screening across 199 potential neurotoxic targets or key molecular initiating events (MIEs). The model demonstrates robust predictive performance, achieving an area under the receiver operating characteristic curve (AUCROC) of 0.923 on the test set. Additionally, ChemNTP's attention mechanism highlights critical residues in binding targets and key functional groups or atoms in molecules, offering insights into the structural basis of interactions. Experimental validation through in vitro enzyme activity assays and molecular docking confirmed the binding of eight polybrominated diphenyl ethers (PBDEs) to acetylcholinesterase (AChE). We also provide a user-friendly software interface to facilitate the rapid identification of neurotoxicity targets for emerging environmental pollutants, with potential applications in studying MIEs for more types of toxicity.

Geometric Molecular Graph Representation Learning Model for Drug-Drug Interactions Prediction

Drug-drug interaction (DDI) can trigger many adverse effects in patients and has emerged as a threat to medicine and public health. Therefore, it is important to predict potential drug interactions since it can provide combination strategies of drugs for systematic and effective treatment. Existing deep learning-based methods often rely on DDI functional networks, or use them as an important part of the model information source. However, it is difficult to discover the interactions of a new drug. To address the above limitations, we propose a geometric molecular graph representation learning model (Mol-DDI) for DDI prediction based on the basic assumption that structure determines function. Mol-DDI only considers the covalent and non-covalent bond information of molecules, then it uses the pre-training idea of large-scale models to learn drug molecular representations and predict drug interactions during the fine-tuning process. Experimental results show that the Mol-DDI model outperforms others on the three datasets and performs better in predicting new drug interaction experiments.

Integrated Knowledge Graph and Drug Molecular Graph Fusion via Adversarial Networks for Drug-Drug Interaction Prediction

The Co-administration of multiple drugs can enhance the efficacy of disease treatment by reducing drug resistance and side effects. However, it also raises the risk of adverse drug interactions, presenting a challenging problem in healthcare. Various approaches have been developed to predict drug-drug interactions (DDIs) by leveraging both knowledge graphs and drug attribute information. While these methods have shown promise, they often fail to effectively capture correlations between biomedical information in the knowledge graph and drug properties. This work introduces a novel end-to-end DDI predictor framework based on generative adversarial networks. This framework utilizes a message-passing neural network to capture molecular structure information while employing the knowledge-aware graph attention network to capture the representation of drugs in the knowledge graph through considering the importance of different multihop neighbor nodes and relationships. The dual generative adversarial networks employ two generators and two discriminators in knowledge graph embedding and molecular topology embedding for adversarial training to capture the interrelations and complementary knowledge between molecular structure information and semantic information from the knowledge graph. comprehensive experiments have demonstrated that the proposed method outperforms state-of-the-art algorithms in binary classification, with improvements of 1.0% in accuracy, 0.45% in area under the receiver operating characteristic curve (AUC), 0.24% in area under the precision-recall curve (AUPR), and 0.98% in F1 score. Furthermore, for multiclass classification tasks, improvements were observed across various evaluation metrics, including 0.9% in accuracy, 0.25% in macro precision, 0.2% in macro recall, and 0.28% in macro F1. Additionally, ablation studies were conducted to showcase the effectiveness and robustness of our method in DDI prediction tasks.

KGRLFF: Detecting Drug-Drug Interactions Based on Knowledge Graph Representation Learning and Feature Fusion

Accurate prediction of drug-drug interactions (DDIs) plays an important role in improving the efficiency of drug development and ensuring the safety of combination therapy. Most existing models rely on a single source of information to predict DDIs, and few models can perform tasks on biomedical knowledge graphs. This paper proposes a new hybrid method, namely Knowledge Graph Representation Learning and Feature Fusion (KGRLFF), to fully exploit the information from the biomedical knowledge graph and molecular structure of drugs to better predict DDIs. KGRLFF first uses a Bidirectional Random Walk sampling method based on the PageRank algorithm (BRWP) to obtain higher-order neighborhood information of drugs in the knowledge graph, including neighboring nodes, semantic relations, and higher-order information associated with triple facts. Then, an embedded representation learning model named Knowledge Graph-based Cyclic Recursive Aggregation (KGCRA) is used to learn the embedded representations of drugs by recursively propagating and aggregating messages with drugs as both the source and destination. In addition, the model learns the molecular structures of the drugs to obtain the structured features. Finally, a Feature Representation Fusion Strategy (FRFS) was developed to integrate embedded representations and structured feature representations. Experimental results showed that KGRLFF is feasible for predicting potential DDIs.

DrugDAGT: a dual-attention graph transformer with contrastive learning improves drug-drug interaction prediction

BACKGROUND

Drug-drug interactions (DDIs) can result in unexpected pharmacological outcomes, including adverse drug events, which are crucial for drug discovery. Graph neural networks have substantially advanced our ability to model molecular representations; however, the precise identification of key local structures and the capture of long-distance structural correlations for better DDI prediction and interpretation remain significant challenges.

RESULTS

Here, we present DrugDAGT, a dual-attention graph transformer framework with contrastive learning for predicting multiple DDI types. The dual-attention graph transformer incorporates attention mechanisms at both the bond and atomic levels, thereby enabling the integration of short and long-range dependencies within drug molecules to pinpoint key local structures essential for DDI discovery. Moreover, DrugDAGT further implements graph contrastive learning to maximize the similarity of representations across different views for better discrimination of molecular structures. Experiments in both warm-start and cold-start scenarios demonstrate that DrugDAGT outperforms state-of-the-art baseline models, achieving superior overall performance. Furthermore, visualization of the learned representations of drug pairs and the attention map provides interpretable insights instead of black-box results.

CONCLUSIONS

DrugDAGT provides an effective tool for accurately predicting multiple DDI types by identifying key local chemical structures, offering valuable insights for prescribing medications, and guiding drug development. All data and code of our DrugDAGT can be found at https://github.com/codejiajia/DrugDAGT .

StructNet-DDI: Molecular Structure Characterization-Based ResNet for Prediction of Drug-Drug Interactions

This study introduces a deep learning framework based on SMILES representations of chemical structures to predict drug-drug interactions (DDIs). The model extracts Morgan fingerprints and key molecular descriptors, transforming them into raw graphical features for input into a modified ResNet18 architecture. The deep residual network, enhanced with regularization techniques, efficiently addresses training issues such as gradient vanishing and exploding, resulting in superior predictive performance. Experimental results show that StructNet-DDI achieved an AUC of 99.7%, an accuracy of 94.4%, and an AUPR of 99.9%, demonstrating the model's effectiveness and reliability. These findings highlight that StructNet-DDI can effectively extract crucial features from molecular structures, offering a simple yet robust tool for DDI prediction.

DAS-DDI: A dual-view framework with drug association and drug structure for drug-drug interaction prediction

In drug development and clinical application, drug-drug interaction (DDI) prediction is crucial for patient safety and therapeutic efficacy. However, traditional methods for DDI prediction often overlook the structural features of drugs and the complex interrelationships between them, which affect the accuracy and interpretability of the model. In this paper, a novel dual-view DDI prediction framework, DAS-DDI is proposed. Firstly, a drug association network is constructed based on similarity information among drugs, which could provide rich context information for DDI prediction. Subsequently, a novel drug substructure extraction method is proposed, which could update the features of nodes and chemical bonds simultaneously, improving the comprehensiveness of the feature. Furthermore, an attention mechanism is employed to fuse multiple drug embeddings from different views dynamically, enhancing the discriminative ability of the model in handling multi-view data. Comparative experiments on three public datasets demonstrate the superiority of DAS-DDI compared with other state-of-the-art models under two scenarios.

DSIL-DDI: A Domain-Invariant Substructure Interaction Learning for Generalizable Drug-Drug Interaction Prediction

Drug-drug interactions (DDIs) trigger unexpected pharmacological effects in vivo, often with unknown causal mechanisms. Deep learning methods have been developed to better understand DDI. However, learning domain-invariant representations for DDI remains a challenge. Generalizable DDI predictions are closer to reality than source domain predictions. For existing methods, it is difficult to achieve out-of-distribution (OOD) predictions. In this article, focusing on substructure interaction, we propose DSIL-DDI, a pluggable substructure interaction module that can learn domain-invariant representations of DDIs from source domain. We evaluate DSIL-DDI on three scenarios: the transductive setting (all drugs in test set appear in training set), the inductive setting (test set contains new drugs that were not present in training set), and OOD generalization setting (training set and test set belong to two different datasets). The results demonstrate that DSIL-DDI improve the generalization and interpretability of DDI prediction modeling and provides valuable insights for OOD DDI predictions. DSIL-DDI can help doctors ensuring the safety of drug administration and reducing the harm caused by drug abuse.

MGDDI: A multi-scale graph neural networks for drug-drug interaction prediction

Drug-drug interaction (DDI) prediction is crucial for identifying interactions within drug combinations, especially adverse effects due to physicochemical incompatibility. While current methods have made strides in predicting adverse drug interactions, limitations persist. Most methods rely on handcrafted features, restricting their applicability. They predominantly extract information from individual drugs, neglecting the importance of interaction details between drug pairs. To address these issues, we propose MGDDI, a graph neural network-based model for predicting potential adverse drug interactions. Notably, we use a multiscale graph neural network (MGNN) to learn drug molecule representations, addressing substructure size variations and preventing gradient issues. For capturing interaction details between drug pairs, we integrate a substructure interaction learning module based on attention mechanisms. Our experimental results demonstrate MGDDI's superiority in predicting adverse drug interactions, offering a solution to current methodological limitations.

Deep graph contrastive learning model for drug-drug interaction prediction

Drug-drug interaction (DDI) is the combined effects of multiple drugs taken together, which can either enhance or reduce each other's efficacy. Thus, drug interaction analysis plays an important role in improving treatment effectiveness and patient safety. It has become a new challenge to use computational methods to accelerate drug interaction time and reduce its cost-effectiveness. The existing methods often do not fully explore the relationship between the structural information and the functional information of drug molecules, resulting in low prediction accuracy for drug interactions, poor generalization, and other issues. In this paper, we propose a novel method, which is a deep graph contrastive learning model for drug-drug interaction prediction (DeepGCL for brevity). DeepGCL incorporates a contrastive learning component to enhance the consistency of information between different views (molecular structure and interaction network), which means that the DeepGCL model predicts drug interactions by integrating molecular structure features and interaction network topology features. Experimental results show that DeepGCL achieves better performance than other methods in all datasets. Moreover, we conducted many experiments to analyze the necessity of each component of the model and the robustness of the model, which also showed promising results. The source code of DeepGCL is freely available at https://github.com/jzysj/DeepGCL.

Accurate prediction of drug combination risk levels based on relational graph convolutional network and multi-head attention

BACKGROUND

Accurately identifying the risk level of drug combinations is of great significance in investigating the mechanisms of combination medication and adverse reactions. Most existing methods can only predict whether there is an interaction between two drugs, but cannot directly determine their accurate risk level.

METHODS

In this study, we propose a multi-class drug combination risk prediction model named AERGCN-DDI, utilizing a relational graph convolutional network with a multi-head attention mechanism. Drug-drug interaction events with varying risk levels are modeled as a heterogeneous information graph. Attribute features of drug nodes and links are learned based on compound chemical structure information. Finally, the AERGCN-DDI model is proposed to predict drug combination risk level based on heterogenous graph neural network and multi-head attention modules.

RESULTS

To evaluate the effectiveness of the proposed method, five-fold cross-validation and ablation study were conducted. Furthermore, we compared its predictive performance with baseline models and other state-of-the-art methods on two benchmark datasets. Empirical studies demonstrated the superior performances of AERGCN-DDI.

CONCLUSIONS

AERGCN-DDI emerges as a valuable tool for predicting the risk levels of drug combinations, thereby aiding in clinical medication decision-making, mitigating severe drug side effects, and enhancing patient clinical prognosis.

MASMDDI: multi-layer adaptive soft-mask graph neural network for drug-drug interaction prediction

Accurately predicting Drug-Drug Interaction (DDI) is a critical and challenging aspect of the drug discovery process, particularly in preventing adverse reactions in patients undergoing combination therapy. However, current DDI prediction methods often overlook the interaction information between chemical substructures of drugs, focusing solely on the interaction information between drugs and failing to capture sufficient chemical substructure details. To address this limitation, we introduce a novel DDI prediction method: Multi-layer Adaptive Soft Mask Graph Neural Network (MASMDDI). Specifically, we first design a multi-layer adaptive soft mask graph neural network to extract substructures from molecular graphs. Second, we employ an attention mechanism to mine substructure feature information and update latent features. In this process, to optimize the final feature representation, we decompose drug-drug interactions into pairwise interaction correlations between the core substructures of each drug. Third, we use these features to predict the interaction probabilities of DDI tuples and evaluate the model using real-world datasets. Experimental results demonstrate that the proposed model outperforms state-of-the-art methods in DDI prediction. Furthermore, MASMDDI exhibits excellent performance in predicting DDIs of unknown drugs in two tasks that are more aligned with real-world scenarios. In particular, in the transductive scenario using the DrugBank dataset, the ACC and AUROC and AUPRC scores of MASMDDI are 0.9596, 0.9903, and 0.9894, which are 2% higher than the best performing baseline.

An effective framework for predicting drug-drug interactions based on molecular substructures and knowledge graph neural network

Drug-drug interactions (DDIs) play a central role in drug research, as the simultaneous administration of multiple drugs can have harmful or beneficial effects. Harmful interactions lead to adverse reactions, some of which can be life-threatening, while beneficial interactions can promote efficacy. Therefore, it is crucial for physicians, patients, and the research community to identify potential DDIs. Although many AI-based techniques have been proposed for predicting DDIs, most existing computational models primarily focus on integrating multiple data sources or combining popular embedding methods. Researchers often overlook the valuable information within the molecular structure of drugs or only consider the structural information of drugs, neglecting the relationship or topological information between drugs and other biological objects. In this study, we propose MSKG-DDI - a two-component framework that incorporates the Drug Chemical Structure Graph-based component and the Drug Knowledge Graph-based component to capture multimodal characteristics of drugs. Subsequently, a multimodal fusion neural layer is utilized to explore the complementarity between multimodal representations of drugs. Extensive experiments were conducted using two real-world datasets, and the results demonstrate that MSKG-DDI outperforms other state-of-the-art models in binary-class, multi-class, and multi-label prediction tasks under both transductive and inductive settings. Furthermore, the ablation analysis further confirms the practical usefulness of MSKG-DDI.

SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug-drug interaction prediction

BACKGROUND

Drug-drug interactions (DDI) are prevalent in combination therapy, necessitating the importance of identifying and predicting potential DDI. While various artificial intelligence methods can predict and identify potential DDI, they often overlook the sequence information of drug molecules and fail to comprehensively consider the contribution of molecular substructures to DDI.

RESULTS

In this paper, we proposed a novel model for DDI prediction based on sequence and substructure features (SSF-DDI) to address these issues. Our model integrates drug sequence features and structural features from the drug molecule graph, providing enhanced information for DDI prediction and enabling a more comprehensive and accurate representation of drug molecules.

CONCLUSION

The results of experiments and case studies have demonstrated that SSF-DDI significantly outperforms state-of-the-art DDI prediction models across multiple real datasets and settings. SSF-DDI performs better in predicting DDI involving unknown drugs, resulting in a 5.67% improvement in accuracy compared to state-of-the-art methods.

Comprehensive Review of Drug-Drug Interaction Prediction Based on Machine Learning: Current Status, Challenges, and Opportunities

Detecting drug-drug interactions (DDIs) is an essential step in drug development and drug administration. Given the shortcomings of current experimental methods, the machine learning (ML) approach has become a reliable alternative, attracting extensive attention from the academic and industrial fields. With the rapid development of computational science and the growing popularity of cross-disciplinary research, a large number of DDI prediction studies based on ML methods have been published in recent years. To give an insight into the current situation and future direction of DDI prediction research, we systemically review these studies from three aspects: (1) the classic DDI databases, mainly including databases of drugs, side effects, and DDI information; (2) commonly used drug attributes, which focus on chemical, biological, and phenotypic attributes for representing drugs; (3) popular ML approaches, such as shallow learning-based, deep learning-based, recommender system-based, and knowledge graph-based methods for DDI detection. For each section, related studies are described, summarized, and compared, respectively. In the end, we conclude the research status of DDI prediction based on ML methods and point out the existing issues, future challenges, potential opportunities, and subsequent research direction.

PEB-DDI: A Task-Specific Dual-View Substructural Learning Framework for Drug-Drug Interaction Prediction

Adverse drug-drug interactions (DDIs) pose potential risks in polypharmacy due to unknown physicochemical incompatibilities between co-administered drugs. Recent studies have utilized multi-layer graph neural network architectures to model hierarchical molecular substructures of drugs, achieving excellent DDI prediction performance. While extant substructural frameworks effectively encode interactions from atom-level features, they overlook valuable chemical bond representations within molecular graphs. More critically, given the multifaceted nature of DDI prediction tasks involving both known and novel drug combinations, previous methods lack tailored strategies to address these distinct scenarios. The resulting lack of adaptability impedes further improvements to model performance. To tackle these challenges, we propose PEB-DDI, a DDI prediction learning framework with enhanced substructure extraction. First, the information of chemical bonds is integrated and synchronously updated with the atomic nodes. Then, different dual-view strategies are selected based on whether novel drugs are present in the prediction task. Particularly, we constructed Molecular fingerprint-Molecular graph view for transductive task, and Bipartite graph-Molecular graph view for inductive task. Rigorous evaluations on benchmark datasets underscore PEB-DDI's superior performance. Notably, on DrugBank, it achieves an outstanding accuracy rate of 98.18% when predicting previously unknown interactions among approved drugs. Even when faced with novel drugs, PEB-DDI consistently exhibits outstanding generalization capabilities with an accuracy rate of 88.06%, attributing to the proper migrating of molecular basic structure learning.

MATT-DDI: Predicting multi-type drug-drug interactions via heterogeneous attention mechanisms

The joint use of multiple drugs can result in adverse drug-drug interactions (DDIs) and side effects that harm the body. Accurate identification of DDIs is crucial for avoiding accidental drug side effects and understanding potential mechanisms underlying DDIs. Several computational methods have been proposed for multi-type DDI prediction, but most rely on the similarity profiles of drugs as the drug feature vectors, which may result in information leakage and overoptimistic performance when predicting interactions between new drugs. To address this issue, we propose a novel method, MATT-DDI, for predicting multi-type DDIs based on the original feature vectors of drugs and multiple attention mechanisms. MATT-DDI consists of three main modules: the top k most similar drug pair selection module, heterogeneous attention mechanism module and multi‑type DDI prediction module. Firstly, based on the feature vector of the input drug pair (IDP), k drug pairs that are most similar to the input drug pair from the training dataset are selected according to cosine similarity between drug pairs. Then, the vectors of k selected drug pairs are averaged to obtain a new drug pair (NDP). Next, IDP and NDP are fed into heterogeneous attention modules, including scaled dot product attention and bilinear attention, to extract latent feature vectors. Finally, these latent feature vectors are taken as input of the classification module to predict DDI types. We evaluated MATT-DDI on three different tasks. The experimental results show that MATT-DDI provides better or comparable performance compared to several state-of-the-art methods, and its feasibility is supported by case studies. MATT-DDI is a robust model for predicting multi-type DDIs with excellent performance and no information leakage.

Drug-drug interaction prediction based on local substructure features and their complements

The properties of drugs may undergo changes when multiple drugs are co-administered to treat co-existing or complex diseases, potentially leading to unforeseen drug-drug interactions (DDIs). Therefore, predicting potential drug-drug interactions has been an important task in pharmaceutical research. However, the following challenges remain: (1) existing methods do not work very well in cold-start scenarios, and (2) the interpretability of existing methods is not satisfactory. To address these challenges, we proposed a multi-channel feature fusion method based on local substructure features of drugs and their complements (LSFC). The local substructure features are extracted from each drug, interacted with those of another drug, and then integrated with the global features of two drugs for DDI prediction. We evaluated LSFC on two real-world DDI datasets in worm-start and cold-start scenarios. Comprehensive experiments demonstrate that LSFC consistently improved DDI prediction performance compared with the start-of-the-art methods. Moreover, visual inspection results showed that LSFC can detect crucial substructures of drugs for DDIs, providing interpretable DDI prediction. The source codes and data are available at https://github.com/Zhang-Yang-ops/LSFC.

BDN-DDI: A bilinear dual-view representation learning framework for drug-drug interaction prediction

Drug-drug interactions (DDIs) refer to the potential effects of two or more drugs interacting with each other when used simultaneously, which may lead to adverse reactions or reduced drug efficacy. Accurate prediction of DDIs is a significant concern in recent years. Currently, the drug chemical substructure-based learning method has substantially improved DDIs prediction. However, we notice that most related works ignore the detailed interaction among atoms when extracting the substructure information of drugs. This problem results in incomplete information extraction and may limit the model's predictive ability. In this work, we proposed a novel framework named BDN-DDI (a bilinear dual-view representation learning framework for drug-drug interaction prediction) to infer potential DDIs. In the proposed framework, the encoder consists of six stacked BDN blocks, each of which extracts the feature representation of drug molecules through a bilinear representation extraction layer. The extracted feature is then used to learn embeddings of drug substructures from the single drug learning layer (intra-layer) and the drug-pair learning layer (inter-layer). Finally, the learned embeddings are fed into a decoder to predict DDI events. Based on our experiments, BDN-DDI has an AUROC value of over 99% for the warm-start task. Additionally, it outperformed the state-of-the-art methods by an average of 3.4% for the cold-start tasks. Finally, our method's effectiveness is further validated by visualizing several case studies.

A dual-modal graph learning framework for identifying interaction events among chemical and biotech drugs

Drug-drug interaction (DDI) identification is essential to clinical medicine and drug discovery. The two categories of drugs (i.e. chemical drugs and biotech drugs) differ remarkably in molecular properties, action mechanisms, etc. Biotech drugs are up-to-comers but highly promising in modern medicine due to higher specificity and fewer side effects. However, existing DDI prediction methods only consider chemical drugs of small molecules, not biotech drugs of large molecules. Here, we build a large-scale dual-modal graph database named CB-DB and customize a graph-based framework named CB-TIP to reason event-aware DDIs for both chemical and biotech drugs. CB-DB comprehensively integrates various interaction events and two heterogeneous kinds of molecular structures. It imports endogenous proteins founded on the fact that most drugs take effects by interacting with endogenous proteins. In the modality of molecular structure, drugs and endogenous proteins are two heterogeneous kinds of graphs, while in the modality of interaction, they are nodes connected by events (i.e. edges of different relationships). CB-TIP employs graph representation learning methods to generate drug representations from either modality and then contrastively mixes them to predict how likely an event occurs when a drug meets another in an end-to-end manner. Experiments demonstrate CB-TIP's great superiority in DDI prediction and the promising potential of uncovering novel DDIs.

HF-DDI: Predicting Drug-Drug Interaction Events Based on Multimodal Hybrid Fusion

Drug-drug interactions (DDIs) can have a significant impact on patient safety and health. Predicting potential DDIs before administering drugs to patients is a critical step in drug development and can help prevent adverse drug events. In this study, we propose a novel method called HF-DDI for predicting DDI events based on various drug features, including molecular structure, target, and enzyme information. Specifically, we design our model with both early fusion and late fusion strategies and utilize a score calculation module to predict the likelihood of interactions between drugs. Our model was trained and tested on a large data set of known DDIs, achieving an overall accuracy of 0.948. The results suggest that incorporating multiple drug features can improve the accuracy of DDI event prediction and may be useful for improving drug safety and patient outcomes.

An Integration Framework of Secure Multiparty Computation and Deep Neural Network for Improving Drug-Drug Interaction Predictions

Drug-drug interaction (DDI) is a key concern in drug development and pharmacovigilance. It is important to improve DDI predictions by integrating multisource data from various pharmaceutical companies. Unfortunately, the data privacy and financial interest issues seriously influence the interinstitutional collaborations for DDI predictions. We propose multiparty computation DDI (MPCDDI), a secure MPC-based deep learning framework for DDI predictions. MPCDDI leverages the secret sharing technologies to incorporate the drug-related feature data from multiple institutions and develops a deep learning model for DDI predictions. In MPCDDI, all data transmission and deep learning operations are integrated into secure MPC frameworks to enable high-quality collaboration among pharmaceutical institutions without divulging private drug-related information. The results suggest that MPCDDI is superior to other eight baselines and achieves the similar performance to that of the corresponding plaintext collaborations. More interestingly, MPCDDI significantly outperforms methods that use private data from the single institution. In summary, MPCDDI is an effective framework for promoting collaborative and privacy-preserving drug discovery.

3D graph neural network with few-shot learning for predicting drug-drug interactions in scaffold-based cold start scenario

Understanding drug-drug interactions (DDI) of new drugs is critical for minimizing unexpected adverse drug reactions. The modeling of new drugs is called a cold start scenario. In this scenario, Only a few structural information or physicochemical information about new drug is available. The 3D conformation of drug molecules usually plays a crucial role in chemical properties compared to the 2D structure. 3D graph network with few-shot learning is a promising solution. However, the 3D heterogeneity of drug molecules and the discretization of atomic distributions lead to spatial confusion in few-shot learning. Here, we propose a 3D graph neural network with few-shot learning, Meta3D-DDI, to predict DDI events in cold start scenario. The 3DGNN ensures rotation and translation invariance by calculating atomic pairwise distances, and incorporates 3D structure and distance information in the information aggregation stage. The continuous filter interaction module can continuously simulate the filter to obtain the interaction between the target atom and other atoms. Meta3D-DDI further develops a FSL strategy based on bilevel optimization to transfer meta-knowledge for DDI prediction tasks from existing drugs to new drugs. In addition, the existing cold start setting may cause the scaffold structure information in the training set to leak into the test set. We design scaffold-based cold start scenario to ensure that the drug scaffolds in the training set and test set do not overlap. The extensive experiments demonstrate that our architecture achieves the SOTA performance for DDI prediction under scaffold-based cold start scenario on two real-world datasets. The visual experiment shows that Meta3D-DDI significantly improves the learning for DDI prediction of new drugs. We also demonstrate how Meta3D-DDI can reduce the amount of data required to make meaningful DDI predictions.

Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications

Because of the high research and development cost of new drugs, the long development process of new drugs, and the high failure rate at later stages, combining past drugs has gradually become a more economical and attractive alternative. However, the ensuing problem of drug-drug interactions (DDIs) urgently need to be solved, and combination has attracted a lot of attention from pharmaceutical researchers. At present, DDI is often evaluated and investigated from two perspectives: pharmacodynamics and pharmacokinetics. However, in some special cases, DDI cannot be accurately evaluated from a single perspective. Therefore, this review describes and compares the current DDI evaluation methods based on two aspects: pharmacokinetic interaction and pharmacodynamic interaction. The methods summarized in this paper mainly include probe drug cocktail methods, liver microsome and hepatocyte models, static models, physiologically based pharmacokinetic models, machine learning models, in vivo comparative efficacy studies, and in vitro static and dynamic tests. This review aims to serve as a useful guide for interested researchers to promote more scientific accuracy and clinical practical use of DDI studies.

Comprehensive evaluation of deep and graph learning on drug-drug interactions prediction

Recent advances and achievements of artificial intelligence (AI) as well as deep and graph learning models have established their usefulness in biomedical applications, especially in drug-drug interactions (DDIs). DDIs refer to a change in the effect of one drug to the presence of another drug in the human body, which plays an essential role in drug discovery and clinical research. DDIs prediction through traditional clinical trials and experiments is an expensive and time-consuming process. To correctly apply the advanced AI and deep learning, the developer and user meet various challenges such as the availability and encoding of data resources, and the design of computational methods. This review summarizes chemical structure based, network based, natural language processing based and hybrid methods, providing an updated and accessible guide to the broad researchers and development community with different domain knowledge. We introduce widely used molecular representation and describe the theoretical frameworks of graph neural network models for representing molecular structures. We present the advantages and disadvantages of deep and graph learning methods by performing comparative experiments. We discuss the potential technical challenges and highlight future directions of deep and graph learning models for accelerating DDIs prediction.

Retrosynthesis prediction using an end-to-end graph generative architecture for molecular graph editing

Retrosynthesis planning, the process of identifying a set of available reactions to synthesize the target molecules, remains a major challenge in organic synthesis. Recently, computer-aided synthesis planning has gained renewed interest and various retrosynthesis prediction algorithms based on deep learning have been proposed. However, most existing methods are limited to the applicability and interpretability of model predictions, and further improvement of predictive accuracy to a more practical level is still required. In this work, inspired by the arrow-pushing formalism in chemical reaction mechanisms, we present an end-to-end architecture for retrosynthesis prediction called Graph2Edits. Specifically, Graph2Edits is based on graph neural network to predict the edits of the product graph in an auto-regressive manner, and sequentially generates transformation intermediates and final reactants according to the predicted edits sequence. This strategy combines the two-stage processes of semi-template-based methods into one-pot learning, improving the applicability in some complicated reactions, and also making its predictions more interpretable. Evaluated on the standard benchmark dataset USPTO-50k, our model achieves the state-of-the-art performance for semi-template-based retrosynthesis with a promising 55.1% top-1 accuracy.

MSEDDI: Multi-Scale Embedding for Predicting Drug-Drug Interaction Events

A norm in modern medicine is to prescribe polypharmacy to treat disease. The core concern with the co-administration of drugs is that it may produce adverse drug-drug interaction (DDI), which can cause unexpected bodily injury. Therefore, it is essential to identify potential DDI. Most existing methods in silico only judge whether two drugs interact, ignoring the importance of interaction events to study the mechanism implied in combination drugs. In this work, we propose a deep learning framework named MSEDDI that comprehensively considers multi-scale embedding representations of the drug for predicting drug-drug interaction events. In MSEDDI, we design three-channel networks to process biomedical network-based knowledge graph embedding, SMILES sequence-based notation embedding, and molecular graph-based chemical structure embedding, respectively. Finally, we fuse three heterogeneous features from channel outputs through a self-attention mechanism and feed them to the linear layer predictor. In the experimental section, we evaluate the performance of all methods on two different prediction tasks on two datasets. The results show that MSEDDI outperforms other state-of-the-art baselines. Moreover, we also reveal the stable performance of our model in a broader sample set via case studies.

Recent development of machine learning models for the prediction of drug-drug interactions

Polypharmacy, the co-administration of multiple drugs, has become an area of concern as the elderly population grows and an unexpected infection, such as COVID-19 pandemic, keeps emerging. However, it is very costly and time-consuming to experimentally examine the pharmacological effects of polypharmacy. To address this challenge, machine learning models that predict drug-drug interactions (DDIs) have actively been developed in recent years. In particular, the growing volume of drug datasets and the advances in machine learning have facilitated the model development. In this regard, this review discusses the DDI-predicting machine learning models that have been developed since 2018. Our discussion focuses on dataset sources used to develop the models, featurization approaches of molecular structures and biological information, and types of DDI prediction outcomes from the models. Finally, we make suggestions for research opportunities in this field.

A dual graph neural network for drug-drug interactions prediction based on molecular structure and interactions

Expressive molecular representation plays critical roles in researching drug design, while effective methods are beneficial to learning molecular representations and solving related problems in drug discovery, especially for drug-drug interactions (DDIs) prediction. Recently, a lot of work has been put forward using graph neural networks (GNNs) to forecast DDIs and learn molecular representations. However, under the current GNNs structure, the majority of approaches learn drug molecular representation from one-dimensional string or two-dimensional molecular graph structure, while the interaction information between chemical substructure remains rarely explored, and it is neglected to identify key substructures that contribute significantly to the DDIs prediction. Therefore, we proposed a dual graph neural network named DGNN-DDI to learn drug molecular features by using molecular structure and interactions. Specifically, we first designed a directed message passing neural network with substructure attention mechanism (SA-DMPNN) to adaptively extract substructures. Second, in order to improve the final features, we separated the drug-drug interactions into pairwise interactions between each drug's unique substructures. Then, the features are adopted to predict interaction probability of a DDI tuple. We evaluated DGNN-DDI on real-world dataset. Compared to state-of-the-art methods, the model improved DDIs prediction performance. We also conducted case study on existing drugs aiming to predict drug combinations that may be effective for the novel coronavirus disease 2019 (COVID-19). Moreover, the visual interpretation results proved that the DGNN-DDI was sensitive to the structure information of drugs and able to detect the key substructures for DDIs. These advantages demonstrated that the proposed method enhanced the performance and interpretation capability of DDI prediction modeling.

R2-DDI: relation-aware feature refinement for drug-drug interaction prediction

Precisely predicting the drug-drug interaction (DDI) is an important application and host research topic in drug discovery, especially for avoiding the adverse effect when using drug combination treatment for patients. Nowadays, machine learning and deep learning methods have achieved great success in DDI prediction. However, we notice that most of the works ignore the importance of the relation type when building the DDI prediction models. In this work, we propose a novel R$^2$-DDI framework, which introduces a relation-aware feature refinement module for drug representation learning. The relation feature is integrated into drug representation and refined in the framework. With the refinement features, we also incorporate the consistency training method to regularize the multi-branch predictions for better generalization. Through extensive experiments and studies, we demonstrate our R$^2$-DDI approach can significantly improve the DDI prediction performance over multiple real-world datasets and settings, and our method shows better generalization ability with the help of the feature refinement design.

DSN-DDI: an accurate and generalized framework for drug-drug interaction prediction by dual-view representation learning

Drug-drug interaction (DDI) prediction identifies interactions of drug combinations in which the adverse side effects caused by the physicochemical incompatibility have attracted much attention. Previous studies usually model drug information from single or dual views of the whole drug molecules but ignore the detailed interactions among atoms, which leads to incomplete and noisy information and limits the accuracy of DDI prediction. In this work, we propose a novel dual-view drug representation learning network for DDI prediction ('DSN-DDI'), which employs local and global representation learning modules iteratively and learns drug substructures from the single drug ('intra-view') and the drug pair ('inter-view') simultaneously. Comprehensive evaluations demonstrate that DSN-DDI significantly improved performance on DDI prediction for the existing drugs by achieving a relatively improved accuracy of 13.01% and an over 99% accuracy under the transductive setting. More importantly, DSN-DDI achieves a relatively improved accuracy of 7.07% to unseen drugs and shows the usefulness for real-world DDI applications. Finally, DSN-DDI exhibits good transferability on synergistic drug combination prediction and thus can serve as a generalized framework in the drug discovery field.

A new framework for drug-disease association prediction combing light-gated message passing neural network and gated fusion mechanism

With the development of research on the complex aetiology of many diseases, computational drug repositioning methodology has proven to be a shortcut to costly and inefficient traditional methods. Therefore, developing more promising computational methods is indispensable for finding new candidate diseases to treat with existing drugs. In this paper, a model integrating a new variant of message passing neural network and a novel-gated fusion mechanism called GLGMPNN is proposed for drug-disease association prediction. First, a light-gated message passing neural network (LGMPNN), including message passing, aggregation and updating, is proposed to separately extract multiple pieces of information from the similarity networks and the association network. Then, a gated fusion mechanism consisting of a forget gate and an output gate is applied to integrate the multiple pieces of information to extent. The forget gate calculated by the multiple embeddings is built to integrate the association information into the similarity information. Furthermore, the final node representations are controlled by the output gate, which fuses the topology information of the networks and the initial similarity information. Finally, a bilinear decoder is adopted to reconstruct an adjacency matrix for drug-disease associations. Evaluated by 10-fold cross-validations, GLGMPNN achieves excellent performance compared with the current models. The following studies show that our model can effectively discover novel drug-disease associations.

Learning size-adaptive molecular substructures for explainable drug-drug interaction prediction by substructure-aware graph neural network

Drug-drug interactions (DDIs) can trigger unexpected pharmacological effects on the body, and the causal mechanisms are often unknown. Graph neural networks (GNNs) have been developed to better understand DDIs. However, identifying key substructures that contribute most to the DDI prediction is a challenge for GNNs. In this study, we presented a substructure-aware graph neural network, a message passing neural network equipped with a novel substructure attention mechanism and a substructure-substructure interaction module (SSIM) for DDI prediction (SA-DDI). Specifically, the substructure attention was designed to capture size- and shape-adaptive substructures based on the chemical intuition that the sizes and shapes are often irregular for functional groups in molecules. DDIs are fundamentally caused by chemical substructure interactions. Thus, the SSIM was used to model the substructure-substructure interactions by highlighting important substructures while de-emphasizing the minor ones for DDI prediction. We evaluated our approach in two real-world datasets and compared the proposed method with the state-of-the-art DDI prediction models. The SA-DDI surpassed other approaches on the two datasets. Moreover, the visual interpretation results showed that the SA-DDI was sensitive to the structure information of drugs and was able to detect the key substructures for DDIs. These advantages demonstrated that the proposed method improved the generalization and interpretation capability of DDI prediction modeling.

Multi-type feature fusion based on graph neural network for drug-drug interaction prediction

Background

Drug-Drug interactions (DDIs) are a challenging problem in drug research. Drug combination therapy is an effective solution to treat diseases, but it can also cause serious side effects. Therefore, DDIs prediction is critical in pharmacology. Recently, researchers have been using deep learning techniques to predict DDIs. However, these methods only consider single information of the drug and have shortcomings in robustness and scalability.

Results

In this paper, we propose a multi-type feature fusion based on graph neural network model (MFFGNN) for DDI prediction, which can effectively fuse the topological information in molecular graphs, the interaction information between drugs and the local chemical context in SMILES sequences. In MFFGNN, to fully learn the topological information of drugs, we propose a novel feature extraction module to capture the global features for the molecular graph and the local features for each atom of the molecular graph. In addition, in the multi-type feature fusion module, we use the gating mechanism in each graph convolution layer to solve the over-smoothing problem during information delivery. We perform extensive experiments on multiple real datasets. The results show that MFFGNN outperforms some state-of-the-art models for DDI prediction. Moreover, the cross-dataset experiment results further show that MFFGNN has good generalization performance.

Conclusions

Our proposed model can efficiently integrate the information from SMILES sequences, molecular graphs and drug-drug interaction networks. We find that a multi-type feature fusion model can accurately predict DDIs. It may contribute to discovering novel DDIs.